Novara Therapeutics to Deliver Contrast Agent for Diagnostic Imaging of Bones
Orthopaedic Research UK and Embryo Ventures have formed Novara Therapeutics. The joint venture company will commercialize a “bone-targeting” contrast agent that improves the quality of normative diagnostic imaging, which is particularly applicable to the diagnosis and treatment of osteoporosis.
Contrast agents, often used to improve medical imaging quality, commonly lack tissue specificity and the ability to provide therapeutic action. The Novara agent aims to specifically support the diagnostic and interventional procedures of osteoporotic fractures.
LATEST NEWS
- 3D Printing High Quality Optics with Blurred Light
May 20, 2024
- Photon Momentum Creates Electron Interaction for Use in Optoelectronics
May 20, 2024
- Active Surfaces Secures $5.6M in Funding for Solar Tech: Week in Brief: 5/17/24
May 17, 2024
- Quantum State Opens Possibility for Advances in Optoelectronics
May 17, 2024
- LED Display Guides Surgery with Real-Time Visuals of Brain Activity
May 16, 2024
- George Mason University Receives Air Force Funding for Imaging, Digital Twins Lab
May 16, 2024
- Intel Appoints Vice President, General Manager of Foundry Arm: People in the News: 5/15/24
May 15, 2024
- Agreements Fortify NVIDIA's Role as Global Partner in Quantum Supercomputing
May 15, 2024